Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2023 financial results before the opening of the U.S. financia...
2023-08-18 19:24:42 ET Summary Fennec Pharmaceuticals has FDA approval for Pedmark, a drug for cisplatin-triggered ototoxicity in children, with promising prospects. Financial concerns include decreasing cash, increasing operational expenses, net loss, and potential need for addit...
2023-08-06 09:00:28 ET Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Conference Call August 3, 2023 08:30 ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive Officer Adrian Haigh - Chief Operating Officer ...
2023-08-03 13:00:53 ET Fennec Pharmaceuticals press release ( NASDAQ: FENC ): Q2 GAAP EPS of -$0.21. Net sales of $3.3M compared to $1.7M in the first quarter of 2023. Research and development expenses decreased by $1.1M for the three months ended June 30, 2023, compar...
~ Growing Physician Awareness and Usage of PEDMARK ® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH...
RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2023 financial results before the opening of the U.S. financi...
RESEARCH TRIANGLE PARK, N.C., June 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced Pedmarqsi™– known as PEDMARK ® in the U.S. – was granted marketing authorization...
2023-05-21 07:21:36 ET Summary Fennec's drug, Pedmark, has FDA approval for cisplatin-triggered ototoxicity in pediatric patients. Its market position is strengthened by notable endorsements and potential European Commission approval. Despite Q1 2023 financials showing decreased c...
2023-05-13 23:34:04 ET Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Conference Call May 11, 2023 08:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive Officer Conference Call Participants Chase...
2023-05-11 06:50:49 ET Fennec Pharmaceuticals press release ( NASDAQ: FENC ): Q1 GAAP EPS of -$0.23 misses by $0.02 . Revenue of $1.68M misses by $0.17M . For further details see: Fennec Pharmaceuticals GAAP EPS of -$0.23 misses by $0.02, revenue of $1.68...
News, Short Squeeze, Breakout and More Instantly...
Fennec Pharmaceuticals Inc. Company Name:
FENC Stock Symbol:
NASDAQ Market:
Fennec Pharmaceuticals Inc. Website:
2024-06-21 13:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-15 10:00:04 ET Chase Knickerbocker from Craig-Hallum issued a price target of $17.00 for FENC on 2024-05-15 08:57:00. The adjusted price target was set to $17.00. At the time of the announcement, FENC was trading at $7.34. The overall price target consensus is at...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 367.5% to $0.2852 on volume of 1,515,686,571 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 32.0% to $6.85 on volume of 599,135,465 shares Crown Electrokinetics Corp. (CR...